The group's principal activity is to develop products such as drugs,genetic diagnostic tests designed to identify genetic markers associated with elevated risk of developing a disease and services for the healthcare industry. The group uses comprehensive population data and proprietary data mining tools to identify and analyze the genetic factors involved in common diseases. The group uses this information in the development of new drugs, dna-based diagnostics and bioinformatics systems and tools. The group develops and applies modern informatics technology to discover new knowledge about health and disease through data mining. The group also develops and markets the clinical genome miner, a computer based discovery system that allows users to perform real-time analysis to study the association between variation in human genes and human disease.
